Lomeguatrib

Drug Profile

Lomeguatrib

Alternative Names: 4-bromothenylguanine; 4-BTG; AZD5896; PaTrin-2

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator KuDOS Pharmaceuticals
  • Class Antineoplastics; Purines
  • Mechanism of Action DNA repair enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Malignant melanoma; Solid tumours

Most Recent Events

  • 04 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and Cancer therapeutic trials sections
  • 01 Jun 2004 Phase-II clinical trials in Solid tumours in USA (PO)
  • 20 Aug 2003 Phase-II clinical trials in Colorectal cancer in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top